Long-Term Implantable Glucose Monitoring Systems: Regulatory Strategy for FDA Premarket Approval and Global Market Access

Read full text Summarise with VIRAT
Authors: Priyanka Savaliyav, Priyalben Patel, Sanjanaben Tejani, Peivand Pirouzi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Long-term implantable continuous glucose monitoring systems represent an innovative approach to diabetes management, utilizing subcutaneously implanted sensors capable of monitoring glucose levels for extended periods of up to 180 days. These systems address limitations of conventional short-term CGM sensors that require frequent replacement, improving patient convenience and potentially enhancing monitoring adherence. The implantable sensor design introduces unique regulatory considerations including surgical implantation and removal procedures, long-term biocompatibility, and tissue-sensor interface stability over extended wear periods. As implantable diagnostic devices where erroneous readings could result in inappropriate therapeutic decisions with serious consequences, these systems are classified as Class III devices requiring FDA Premarket Approval (PMA). This article examines the regulatory framework for long-term implantable CGM systems, including classification rationale, applicable standards, clinical evidence requirements, and strategic pathways for market authorization. Keywords: implantable glucose monitor, fluorescence sensing, Class III medical device, PMA, diabetes mellitus, long-term monitoring, FDA, Health Canada, ISO 13485

Fields of Study & Subjects

Healthcare Regulation Diabetes Management and Research Electrochemical sensors and biosensors

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
25 March 2026
Language
EN